GNH USA

Europe — EMA

Ovaleap (Follitropin Alfa (Genetical Recombination))

GNH USA supplies Ovaleap (Follitropin Alfa), a gonadotropin for controlled ovarian stimulation in IVF and ovulation induction. Request a quote for supply.

Follitropin Alfa (Genetical Recombination)

Request sourcing

1
Pack/s

What is Follitropin Alfa (Genetical Recombination)?

Follitropin alfa, the active ingredient in Ovaleap, is a gonadotropin presented as a 75 IU/0.5 ml solution for subcutaneous injection use. It stimulates ovarian follicle development in women undergoing assisted reproductive technology.

GNH USA supplies Ovaleap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

What is Follitropin Alfa (Genetical Recombination) used for?

Ovaleap is a recombinant follicle‑stimulating hormone used in the gonadotropin pathway to support assisted reproduction and ovulation induction. - In vitro fertilisation (IVF) cycles: promotes the growth of multiple ovarian follicles to enable egg retrieval. - Intracytoplasmic sperm injection (ICSI) cycles: enhances follicular development for precise sperm injection procedures. - Ovulation induction in anovulatory women: facilitates follicular maturation when combined with other agents such as hCG.

What are the side effects of Follitropin Alfa (Genetical Recombination)?

Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous site. - Ovarian hyperstimulation syndrome (mild): abdominal bloating and mild discomfort. - Headache: transient, often resolves without intervention. - Nausea: mild gastrointestinal upset. - Mood changes: occasional irritability or emotional lability. - Vaginal spotting: light bleeding unrelated to menstrual cycle.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, shortness of breath, or significant abdominal distension. - Ovarian torsion: sudden severe pelvic pain requiring emergency evaluation. - Thromboembolic events: rare clot formation in veins or arteries. - Allergic reaction: rash, itching, or anaphylaxis. - Visual disturbances: blurred vision or ocular discomfort. - Persistent ovarian cysts: cysts lasting beyond the treatment cycle.

What precautions apply to Follitropin Alfa (Genetical Recombination)?

Before using Ovaleap, consider the following precautions: - Assess ovarian reserve: evaluate baseline hormone levels and antral follicle count. - Monitor for OHSS: schedule regular ultrasound and estradiol assessments. - Adjust dosage in renal or hepatic impairment: follow prescriber guidance. - Avoid use in uncontrolled thyroid disease: stabilize thyroid function first. - Counsel on signs of severe OHSS: educate patients to report rapid weight gain or shortness of breath. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Follitropin Alfa (Genetical Recombination) interact with?

Major Interactions (Avoid): - hCG or LH analogues administered concurrently: may exacerbate ovarian hyperstimulation. - Estrogen‑containing oral contraceptives: can blunt FSH response if not discontinued appropriately.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor for increased bleeding risk if OHSS occurs. - Thyroid hormone therapy: adjust dosing if thyroid function changes during treatment. - Glucocorticoids: may affect ovarian response; monitor follicular development. - Diuretics: can mask early signs of OHSS; observe fluid balance closely. - Antidepressants (SSRIs): monitor for mood changes that could be confused with hormonal effects.

Frequently asked questions

What is Ovaleap used for?+
Ovaleap is a recombinant follicle‑stimulating hormone used to stimulate the development of ovarian follicles in women undergoing assisted reproductive technologies such as in‑vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI), and to induce ovulation in anovulatory women when combined with other hormonal agents.
How does Follitropin alfa work?+
Follitropin alfa mimics natural human follicle‑stimulating hormone (FSH). It binds to FSH receptors on ovarian granulosa cells, activating intracellular cAMP pathways that promote cell proliferation, estrogen production, and the maturation of ovarian follicles, thereby preparing the ovary for ovulation or egg retrieval.
What is the usual dose of Ovaleap?+
The specific dose of Ovaleap is individualized by the prescribing clinician based on the patient’s ovarian reserve, treatment protocol, and response to therapy. Dosing regimens are adjusted throughout the stimulation cycle according to ultrasound and hormonal monitoring.
Is Ovaleap safe during pregnancy or breastfeeding?+
Ovaleap is intended for use before pregnancy to achieve conception. Its safety in established pregnancy has not been established, and it is not recommended during breastfeeding. Women should discuss any concerns with their healthcare provider before starting treatment.
How do I order Ovaleap from GNH USA?+
To order Ovaleap, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.
How does Ovaleap compare with other gonadotropins?+
Ovaleap is a recombinant FSH product, offering high purity and consistent activity compared with urinary‑derived gonadotropins. It provides predictable dosing and lower risk of immunogenic reactions, making it a preferred option for many fertility specialists when precise follicular control is required.
What are the storage and handling requirements for Ovaleap?+
Ovaleap must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the vial to reach room temperature for a few minutes, inspect for particulate matter, and use aseptic technique for subcutaneous injection.
How is Ovaleap administered?+
Ovaleap is supplied as a sterile solution for subcutaneous injection. The prescribed dose is drawn into a sterile syringe and injected into the abdominal wall or thigh, rotating injection sites to minimise local reactions. Administration is performed by the patient or a trained healthcare professional.
What are the most serious risks associated with Ovaleap?+
The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, shortness of breath, and, in rare cases, thromboembolic events or ovarian torsion. Prompt medical attention is required if these symptoms develop.
Who should not use Ovaleap?+
Ovaleap should not be used in women with known hypersensitivity to any component of the product, uncontrolled thyroid disease, active ovarian cysts, or severe ovarian failure. It is also contraindicated in patients with a history of severe OHSS or those who are pregnant.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Follitropin Alfa (Genetical Recombination)
Route
Subcutaneous Use
Manufacturer
Theramex Ireland Limited
Origin
EU

Related products

Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU
Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU
Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU